uniQure (NASDAQ:QURE) Stock Price Expected to Rise, Chardan Capital Analyst Says

uniQure (NASDAQ:QURE) had its price objective upped by analysts at Chardan Capital from $16.00 to $31.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Chardan Capital’s price target points to a potential upside of 77.95% from the stock’s previous close.

A number of other research firms have also commented on QURE. Stifel Nicolaus set a $14.00 price target on uniQure in a research report on Monday, March 2nd. Wolfe Research began coverage on uniQure in a research note on Monday, February 23rd. They set a “peer perform” rating for the company. William Blair restated a “market perform” rating on shares of uniQure in a report on Tuesday, November 11th. Wells Fargo & Company upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $15.00 to $60.00 in a report on Monday. Finally, HC Wainwright reissued a “buy” rating and set a $70.00 price objective on shares of uniQure in a research report on Tuesday, February 10th. Nine investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $41.33.

uniQure Trading Up 22.1%

Shares of QURE stock traded up $3.15 on Monday, hitting $17.42. The stock had a trading volume of 11,932,201 shares, compared to its average volume of 3,653,700. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25. uniQure has a twelve month low of $7.76 and a twelve month high of $71.50. The company has a fifty day moving average price of $22.04 and a two-hundred day moving average price of $29.63. The firm has a market cap of $1.09 billion, a P/E ratio of -5.05 and a beta of 0.73.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.93) by $0.37. The business had revenue of $5.57 million for the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%. As a group, analysts forecast that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Transactions at uniQure

In other news, Director Jack Kaye sold 6,390 shares of the firm’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the completion of the transaction, the director owned 20,439 shares in the company, valued at $557,575.92. This trade represents a 23.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert Gut sold 25,613 shares of uniQure stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the sale, the director directly owned 32,342 shares in the company, valued at approximately $796,260.04. This represents a 44.19% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 81,399 shares of company stock worth $1,527,645. 4.79% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Private Trust Co. NA bought a new position in shares of uniQure during the third quarter worth approximately $28,000. Jones Financial Companies Lllp increased its stake in uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares during the last quarter. CIBC Private Wealth Group LLC acquired a new position in shares of uniQure during the 3rd quarter worth $50,000. Torren Management LLC acquired a new position in uniQure during the fourth quarter worth about $28,000. Finally, FNY Investment Advisers LLC lifted its stake in uniQure by 76.7% in the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 718 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Major analyst upgrades lift sentiment — Wells Fargo upgraded uniQure to “overweight” with a $60 price target and RBC raised its rating to “outperform” with a $35 target; both moves signal large upside expectations and likely contributed to buying interest. Wells Fargo Upgrade
• Positive Sentiment: Market rallied on regulatory staffing news — reports that FDA CBER official Vinay Prasad plans to exit in April triggered a sectorwide bounce and was cited as a proximate cause of uniQure’s intraday surge. This appears to have reduced near-term regulatory overhang in traders’ eyes. uniQure stock surges on FDA official departure
• Neutral Sentiment: Analysts flag upcoming clinical catalysts — coverage noting uniQure among biotechs with asymmetric upside ahead of binary drug-readout events may support speculative interest, but outcomes remain binary and high-risk. Analyst Interest Ahead of Catalysts
• Neutral Sentiment: Retail/celebrity portfolio coverage — stories noting large unrealized losses in a public investor’s portfolio draw attention but have limited direct impact on fundamentals. TipRanks coverage
• Negative Sentiment: Class-action lawsuits announced — Portnoy Law Firm and Rosen Law Firm have publicized securities class actions covering purchases between Sept. 24 and Oct. 31, 2025; potential legal exposure and related PR/settlement risk add downside pressure and uncertainty. Portnoy Law Firm class action
• Negative Sentiment: Ongoing FDA scrutiny and changing trial demands — coverage (Genetic Engineering & Biotechnology News, Yahoo Finance) highlights that FDA requests around the AMT-130 program have reshaped expectations; regulatory friction remains a material risk for timelines and approvals. Regulatory scrutiny coverage

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.